Synergistic interaction between highly specific cyclooxygenase-2 inhibitor, MF-tricyclic and lovastatin in murine colorectal cancer cell lines

  • Authors:
    • Wojciech Feleszko
    • Ahmad Jalili
    • Dominika Olszewska
    • Izabela Mlynarczuk
    • Tomasz Grzela
    • Adam Giermasz
    • Marek Jakobisiak
  • View Affiliations

  • Published online on: Monday, July 1, 2002
  • Pages: 879-885
  • DOI: 10.3892/or.9.4.879

Abstract

Statins, anti-hypercholesterolemic agents, have previously been reported to induce apoptosis and exert antitumor activity when combined with other antitumor agents. The potential of lovastatin in combination with highly specific COX-2 inhibitor (MF-tricyclic) to induce anti-proliferative activity against tumour cells was evaluated using the combination index (CI) method. Murine colorectal cancer (colon-26, CMT-93), melanoma (B16F10) and human bladder carcinoma cells (T24) were tested. Exposure of colon-26 and CMT-93 cells resulted in synergistic interactions in both cell lines with CI<1 for 20-80% inhibition of cell growth in both cell lines. This synergy was not observed in the B16F10 melanoma and T24 bladder carcinoma cells. MF-tricyclic (40 μg/ml), augmented lovastatin-induced apoptosis up to 2.5-fold in colon-26 cancer cells. Combination of a specific COX-2 inhibitor, MF-tricyclic, may increase antiproliferative effects of lovastatin in colon cancer cells and this effect was due to an augmented apoptosis.
Journal Cover

July 2002
Volume 9 Issue 4

Print ISSN: 1021-335X
Online ISSN:1791-2431

2013 Impact Factor: 2.191
Ranked #33/202 Oncology
(total number of cites)

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Feleszko, W., Jalili, A., Olszewska, D., Mlynarczuk, I., Grzela, T., Giermasz, A., & Jakobisiak, M. (2002). Synergistic interaction between highly specific cyclooxygenase-2 inhibitor, MF-tricyclic and lovastatin in murine colorectal cancer cell lines. Oncology Reports, 9(4), 879-885.
MLA
Feleszko, Jalili, Olszewska, Mlynarczuk, Grzela, Giermasz, and Marek Jakobisiak. "Synergistic interaction between highly specific cyclooxygenase-2 inhibitor, MF-tricyclic and lovastatin in murine colorectal cancer cell lines." Oncology Reports Oncology Reports 9.4 (2002): 879-885.
Chicago
Feleszko, Jalili, Olszewska, Mlynarczuk, Grzela, Giermasz, and Marek Jakobisiak. "Synergistic interaction between highly specific cyclooxygenase-2 inhibitor, MF-tricyclic and lovastatin in murine colorectal cancer cell lines." Oncology Reports Oncology Reports 9 no. 4 (2002): 879-885.